Unexpected behavior of neutrophils unveiled by researchers at Stanford University could lead to a new type of immunotherapy to treat cancer. Although various studies have suggested that these cells are harmful due to their immunosuppressive characteristics, the scientists saw in them an opportunity to redirect them and eliminate tumors.
Inmune Bio Inc. CEO Raymond Tesi told BioWorld his firm is taking an “oncology-style” approach to Alzheimer’s disease (AD) as the firm tests next-generation tumor necrosis factor (TNF) inhibitor XPro-1595 against neuroinflammation.